# US 2012/0258974 A1 · Use of a2b adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0258974 A1
- Document ID: US20120258974A1
- Status: Published application
- Kind: A1
- Application number: 13/440,926
- Filed: 2012-04-05
- Published: 2012-10-11
- Earliest claimed: 2011-04-07
- Assignees: Gilead Sciences, Inc.
- Inventors: Luiz Belardinelli; Hongyan Zhong; Dewan Zeng
- Web page: https://patentgrep.com/patent/US20120258974A1

## CPC

- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/02: Suppositories; Bougies; Bases therefor; {Ovules}(apparatus for making A61J3/08; devices for introducing into the body A61M31/00)
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are methods of improving the cardiac condition of post-myocardial infarction (MI) patients and reducing cardiovascular death and hospitalization due to heart failure or arrhythmias, by administering a therapeutically effective amount of an A2B adenosine receptor antagonist.

## Claims

### Claim 1

A method of treating heart failure and/or arrhythmia in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.

### Claim 2 (depends on 1)

The method of claim 1, wherein death or hospitalization is reduced by treatment of the heart failure and/or arrhythmia.

### Claim 3

A method of reducing the progression of heart failure in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.

### Claim 4

A method of reducing arrhythmia in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.

### Claim 5

A method of reducing the incidence of sudden cardiac death in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.

### Claim 6

A method of increasing the left ventricle ejection fraction (LVEF) in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.

### Claim 7

A method of inhibiting left ventricle enlargement in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.

### Claim 8

A method of reducing left ventricle end systolic volume in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.

### Claim 9

A method of reducing left ventricle end diastolic volume in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.

### Claim 10

A method of ameliorating left ventricle dysfunction in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.

### Claim 11

A method of improving myocardial contractibility in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.

### Claim 12

A method of reducing the release of IL-6, TNFa, BNP, or ST2 (suppression of tumorigenicity 2) from a cardiac cell in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.

### Claim 13 (depends on 1)

The method of claim 1, wherein the A2B adenosine receptor antagonist is a 8-cyclic xanthine derivative.

### Claim 14 (depends on 1)

The method of claim 1, wherein the A2B adenosine receptor antagonist is a compound of Formula I or II:
wherein:
R1 and R2 are independently chosen from hydrogen, optionally substituted alkyl, or a group -D-E, in which D is a covalent bond or alkylene, and E is optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted alkenyl or optionally substituted alkynyl;
R3 is hydrogen, optionally substituted alkyl or optionally substituted cycloalkyl;
X is optionally substituted arylene or optionally substituted heteroarylene;
Y is a covalent bond or alkylene in which one carbon atom can be optionally replaced by —O—, —S—, or —NH—, and is optionally substituted by hydroxy, alkoxy, optionally substituted amino, or —COR, in which R is hydroxy, alkoxy or amino; and
Z is optionally substituted monocyclic aryl or optionally substituted monocyclic heteroaryl; or
Z is hydrogen when X is optionally substituted heteroarylene and Y is a covalent bond;
or a pharmaceutically acceptable salt, tautomer, isomer, a mixture of isomers, or prodrug thereof.

### Claim 15 (depends on 1)

The method of claim 1, wherein the A2B adenosine receptor antagonist is a compound having the chemical formula:
and the name 3-ethyl-1-propyl-8-(1-(3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-1H-purine-2,6(3H,7H)-dione or 3-ethyl-1-propyl-8-(1-((3-(trifluoromethyl)phenyl)methyl)pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione or a pharmaceutically acceptable salt, tautomer, isomer, or a mixture of isomers thereof.

### Claim 16 (depends on 1)

The method of claim 1, wherein the A2B adenosine receptor antagonist is N-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-pyridin-2-yl]-N-ethyl-nicotinamide.

### Claim 17 (depends on 1)

The method of claim 1, wherein the A2B adenosine receptor antagonist is (2-(4-benzyloxy-phenyl)-N-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yl]-acetamide.

### Claim 18 (depends on 1)

The method of claim 1, wherein the MI is acute MI.

### Claim 19 (depends on 18)

The method of claim 18, wherein the MI is ST elevation MI (STEMI) or non-ST elevation MI (NSTEMI).

### Claim 20 (depends on 1)

The method of claim 1, wherein the patient is hemodynamically stable.

### Claim 21 (depends on 1)

The method of claim 1, wherein the administration of the A2B adenosine receptor antagonist starts during the MI or immediately following the MI.

### Claim 22 (depends on 1)

The method of claim 1, wherein the administration of the A2B adenosine receptor antagonist starts after at least about 24 hours following the MI.

### Claim 23 (depends on 22)

The method of claim 22, wherein the administration of the A2B adenosine receptor antagonist starts after at least about 3 days following the MI.

### Claim 24 (depends on 22)

The method of claim 22, wherein the administration of the A2B adenosine receptor antagonist starts after at least about 5 days following the MI.

### Claim 25 (depends on 22)

The method of claim 22, wherein the administration of the A2B adenosine receptor antagonist starts after at least about 7 days following the MI.

### Claim 26 (depends on 1)

The method of claim 1, further comprising administering to the patient an angiotensin-converting enzyme (ACE) inhibitor.

### Claim 27 (depends on 1)

The method of claim 1, wherein the ACE inhibitor is selected from the group consisting of captopril, enalapril, lisinopril, perindopril and ramipril.

### Claim 28 (depends on 1)

The method of claim 1, wherein the patient is human.

### Claim 29 (depends on 1)

The method of claim 1, wherein the administration is systemic, oral, intravenous, intramuscular, intraperitoneal or by inhalation.
